December 8, 2025Blood

Myeloproliferative neoplasms-unclassifiable (MPN-U): A carefully curated series of 30 Mayo Clinic patients

View Full Paper

Ask AI

Bookmark

Authors

Discussion

This analysis compares clinical outcomes and mutations in MPN-U and essential thrombocythemia, suggesting challenges in managing venous thrombosis.

Patients with MPN-U displayed a higher incidence of venous thrombosis compared to the ET group.
Next-generation sequencing revealed key genetic differences including CALR mutations in MPN-U patients.
Evaluation of clinical outcomes showed similar long-term survival rates between MPN-U and ET cohorts.
Challenges remain in the treatment of venous thrombo-embolic events in both MPN-U and essential thrombocythemia.

Abdelaziz et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

Authors

This analysis compares clinical outcomes and mutations in MPN-U and essential thrombocythemia, suggesting challenges in managing venous thrombosis.

Patients with MPN-U displayed a higher incidence of venous thrombosis compared to the ET group.
Next-generation sequencing revealed key genetic differences including CALR mutations in MPN-U patients.
Evaluation of clinical outcomes showed similar long-term survival rates between MPN-U and ET cohorts.
Challenges remain in the treatment of venous thrombo-embolic events in both MPN-U and essential thrombocythemia.

Abdelaziz et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark